Extended Data Fig. 1: CAR T cells in the infusion products are activated and exhausted effector T cells, with comparable features across patients. | Nature Cancer

Extended Data Fig. 1: CAR T cells in the infusion products are activated and exhausted effector T cells, with comparable features across patients.

From: Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

Extended Data Fig. 1: CAR T cells in the infusion products are activated and exhausted effector T cells, with comparable features across patients.The alt text for this image may have been generated using AI.

(a) Representative example of EGFRvIII CAR T cells staining in the infusion product. (b) Scatterplot shows proportion of EGFRvIII CAR T cells staining in the infusion products of the patients. (c) Representative example of CD4/CD8 staining in EGFRvIII CAR T cells staining in the infusion product. (d) Scatterplot shows proportion of CD4 T cells within EGFRvIII CAR T cells in the infusion products of the patients. (e) Representative example of CD127/CD25 regulatory T cells staining in the infusion product. (f) Representative example of Foxp3 expression in the different CD4 T-cell subsets in the infusion product. (g) Expression of CD4, CD40LG, Foxp3 in the infusion product as detected by RNA in scRNAseq data projected on a UMAP. (h) Representative example of CD45RA/CD127 staining in CD4 CAR T cells in the infusion product (P1, left; P4, right). (i) Representative example of CD45RA/CD127 staining in CD8 CAR T cells in the infusion product (P1, left; P4, right). (j) Representative example of PD1, CD39, Ki67 staining in CD8 T cells in the infusion product (P1, top; P4, bottom). (k) Heatmap shows expression in CD8 T cells in the infusion product of P1 and P4 as compared to a normal donor.

Source data

Back to article page